Tourmaline Bio Inc. (TRML)
Tourmaline Bio Statistics
Share Statistics
Tourmaline Bio has 25.69M shares outstanding. The number of shares has increased by 0.15% in one year.
| Shares Outstanding | 25.69M |
| Shares Change (YoY) | 0.15% |
| Shares Change (QoQ) | 0.17% |
| Owned by Institutions (%) | 88.73% |
| Shares Floating | 16.04M |
| Failed to Deliver (FTD) Shares | 245 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 2.33M, so 9.08% of the outstanding shares have been sold short.
| Short Interest | 2.33M |
| Short % of Shares Out | 9.08% |
| Short % of Float | 14.93% |
| Short Ratio (days to cover) | 11.16 |
Valuation Ratios
The PE ratio is -7.02 and the forward PE ratio is -4.67. Tourmaline Bio's PEG ratio is 0.1.
| PE Ratio | -7.02 |
| Forward PE | -4.67 |
| PS Ratio | 0 |
| Forward PS | 2.9 |
| PB Ratio | 1.71 |
| P/FCF Ratio | -6.65 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tourmaline Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.18, with a Debt / Equity ratio of 0.
| Current Ratio | 30.18 |
| Quick Ratio | 30.18 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-989.32K |
| Employee Count | 74 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -37.37% in the last 52 weeks. The beta is 2.16, so Tourmaline Bio's price volatility has been higher than the market average.
| Beta | 2.16 |
| 52-Week Price Change | -37.37% |
| 50-Day Moving Average | 14.67 |
| 200-Day Moving Average | 19.01 |
| Relative Strength Index (RSI) | 32.62 |
| Average Volume (20 Days) | 332.07K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -89.73M |
| Net Income | -73.21M |
| EBITDA | -89.73M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.89 |
Balance Sheet
The company has 30.51M in cash and 244K in debt, giving a net cash position of 30.26M.
| Cash & Cash Equivalents | 30.51M |
| Total Debt | 244K |
| Net Cash | 30.26M |
| Retained Earnings | -135.26M |
| Total Assets | 309M |
| Working Capital | 259.93M |
Cash Flow
In the last 12 months, operating cash flow was -77.26M and capital expenditures -9K, giving a free cash flow of -77.27M.
| Operating Cash Flow | -77.26M |
| Capital Expenditures | -9K |
| Free Cash Flow | -77.27M |
| FCF Per Share | -3.05 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRML does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TRML is $50, which is 301% higher than the current price. The consensus rating is "Buy".
| Price Target | $50 |
| Price Target Difference | 301% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Oct 20, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 20, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 20.55 |
| Piotroski F-Score | 1 |